Literature DB >> 15004528

Cancer stem cells persist in many cancer cell lines.

Takao Setoguchi1, Tetsuya Taga, Toru Kondo.   

Abstract

Both stem cells and cancer cells are thought to be capable of unlimited proliferation. Paradoxically, however, some cancers seem to contain stem-like cells (cancer stem cells). To help resolve this paradox, we investigated whether established malignant cell lines, which have been maintained over years in culture, contain a subpopulation of stem cells. We have shown that four cancer cell lines contain a small side population (SP), which, in many normal tissues, is enriched for stem cells of the tissue. We have also shown that SP cells in C6 glioma cell line, but not non-SP cells, can generate both SP and non-SP cells in culture and are largely responsible for the in vivo malignancy of this cell line. We propose that many cancer cell lines contain a minor subpopulation of stem cells that is enriched in a SP, can be maintained indefinitely in culture, and is crucial for their malignancy.

Entities:  

Mesh:

Year:  2004        PMID: 15004528     DOI: 10.4161/cc.3.4.799

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  53 in total

Review 1.  Targeting Notch to target cancer stem cells.

Authors:  Antonio Pannuti; Kimberly Foreman; Paola Rizzo; Clodia Osipo; Todd Golde; Barbara Osborne; Lucio Miele
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

2.  Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells.

Authors:  Sudha Krishnamurthy; Zhihong Dong; Dmitry Vodopyanov; Atsushi Imai; Joseph I Helman; Mark E Prince; Max S Wicha; Jacques E Nör
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

Review 3.  Human adult stem cells as the target cells for the initiation of carcinogenesis and for the generation of "cancer stem cells".

Authors:  James E Trosko
Journal:  Int J Stem Cells       Date:  2008-11       Impact factor: 2.500

4.  Cluster of differentiation 44- and octamer-binding transcription factor-4-positive stem-like osteosarcoma cells involved in tumor development.

Authors:  Lan-Mei Liu; Hong-Ai Sun; Xiao Li; Yang Chen; Bao-Fu Wei; Xiu-Ju Li
Journal:  Oncol Lett       Date:  2015-04-29       Impact factor: 2.967

Review 5.  Circulating Tumor Cells in Early-Stage Breast Cancer.

Authors:  A D Hartkopf; M Banys; N Krawczyk; M Wallwiener; H Schneck; H Neubauer; T Fehm
Journal:  Geburtshilfe Frauenheilkd       Date:  2011-12       Impact factor: 2.915

6.  Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors.

Authors:  I Ferrer; E M Verdugo-Sivianes; M A Castilla; R Melendez; J J Marin; S Muñoz-Galvan; J L Lopez-Guerra; B Vieites; M J Ortiz-Gordillo; J M De León; J M Praena-Fernandez; M Perez; J Palacios; A Carnero
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

7.  Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma.

Authors:  Po Zhao; Yazhuo Li; Yali Lu
Journal:  BMC Cancer       Date:  2010-05-20       Impact factor: 4.430

8.  Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells.

Authors:  Margherita Gaviraghi; Patrizia Tunici; Silvia Valensin; Marco Rossi; Cinzia Giordano; Letizia Magnoni; Mario Dandrea; Licia Montagna; Rossana Ritelli; Aldo Scarpa; Annette Bakker
Journal:  Biosci Rep       Date:  2011-02       Impact factor: 3.840

Review 9.  Breast cancer stem cells: tools and models to rely on.

Authors:  Emmanuelle Charafe-Jauffret; Christophe Ginestier; Daniel Birnbaum
Journal:  BMC Cancer       Date:  2009-06-25       Impact factor: 4.430

10.  Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells.

Authors:  M Hirotsu; T Setoguchi; Y Matsunoshita; H Sasaki; H Nagao; H Gao; K Sugimura; S Komiya
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.